Eptifibatide

證據等級: L5

預測適應症: 10 個

EPTIFIBATIDE: From Acute Coronary Syndrome to Hemoglobinopathy (Sickle Cell Disease)

Note on indication selection: This Evidence Pack (TW-DB00063-multi) contains 10 TxGNN-predicted indications for eptifibatide. The #1-ranked prediction by raw score (rheumatoid arthritis, 99.99%) has zero clinical trials, zero literature, and an unfilled ("pending") rationale — it is an unvalidated model output only. By contrast, rank #7 (hemoglobinopathy / sickle cell disease) is the only prediction in this pack with a completed evidence review (1 clinical trial + 4 publications, evidence level L2, decision stage S1). To make this report actually useful for decision-making, it is built around that candidate. All 10 predictions — including rheumatoid arthritis — are listed for transparency in the "Other TxGNN-Predicted Indications" section below.

One-Sentence Summary

Eptifibatide is a GPIIb/IIIa (αIIbβ3) platelet receptor antagonist; based on the literature contained in this evidence pack, it is established for use in acute coronary syndrome (ACS). The TxGNN model predicts it may also be effective for hemoglobinopathy (sickle cell disease), and — unlike the other 9 predictions in this pack — this direction is backed by 1 terminated Phase 1/2 clinical trial and 4 publications, including two studies that directly tested eptifibatide in sickle cell disease patients.

Quick Overview

Item	Content
Original Indication	Not on file in structured regulatory data (drug is not marketed; 0 licenses). Literature in this pack indicates established use in acute coronary syndrome (ACS) as a GPIIb/IIIa antagonist.
Predicted New Indication	Hemoglobinopathy (sickle cell disease spectrum)
TxGNN Prediction Score	99.98% (rank 485 in model output)
Evidence Level	L2 (per pipeline scoring — see caveat below)
Germany Market Status	✗ Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Caveat on Evidence Level: the sole trial (NCT00834899) was Phase 1/2 but Terminated with only 13 of a planned larger cohort enrolled, and the earliest human study (PMID 17916103) tested only 4 patients. Per the formal rule set (L2 = "1 completed Phase 2/3 RCT"), this evidence is better described as preliminary/early-phase rather than a fully completed confirmatory trial — the L2 label reflects that real human testing exists, not that it is conclusive.

Why is This Prediction Reasonable?

Eptifibatide is a synthetic cyclic heptapeptide that antagonizes the platelet αIIbβ3 (GPIIb/IIIa) receptor, blocking the final common pathway of platelet aggregation. This mechanism is well established in acute coronary syndrome, where inhibiting platelet-mediated thrombus formation reduces ischemic complications during and after percutaneous coronary intervention.

Sickle cell disease (and the broader hemoglobinopathy spectrum) shares a pathophysiological feature with ACS: vaso-occlusion. In sickle cell disease, painful crises are driven in part by abnormal platelet activation, platelet-leukocyte-endothelial interactions, and CD40 ligand release, which together promote microvascular occlusion and inflammation — a process mechanistically analogous to the platelet-driven thrombosis eptifibatide is designed to block in ACS. This shared mechanism is the rationale investigators used to test eptifibatide directly in sickle cell patients, rather than a purely computational inference.

Because this exact hypothesis has already been tested in humans (Phase 1 pharmacodynamic study, a pilot efficacy trial, and a terminated Phase 1/2 RCT), this is a case where TxGNN's prediction converges with pre-existing, real clinical investigation — strengthening confidence relative to the other 9 predictions in this pack, all of which are pure graph-based inferences with no clinical follow-up.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00834899	Phase 1/2	Terminated	13	Randomized, double-blind, placebo-controlled study evaluating safety of eptifibatide for acute pain episodes in sickle cell disease. Hypothesis: platelet activation and resultant inflammation contribute to vaso-occlusive crises. Terminated early with only 13 of the planned cohort enrolled, indicating feasibility/recruitment challenges.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
17916103	2007	Phase 1 trial	British Journal of Haematology	First human test of eptifibatide in sickle cell anaemia (4 patients, non-crisis/steady-state). Rationale: platelet reactivity and CD40 ligand release in SCD parallel ACS pathophysiology; safety and pharmacodynamic data were obtained following infusion.
23973010	2013	Pilot clinical study	Thrombosis Research	Pilot study of eptifibatide (αIIbβ3 antagonist) for treatment of acute pain episodes in SCD, evaluating safety and efficacy; contribution of platelet activation to SCD pathogenesis remained uncertain going in.
29322543	2018	Clinical sub-analysis	American Journal of Hematology	Companion analysis examining the effect of eptifibatide on inflammatory markers during acute pain episodes in SCD (linked to the pilot trial above).
22156199	2012	In vitro / microfluidic model	The Journal of Clinical Investigation	Developed an "endothelialized" microfluidic microvasculature model recapitulating microvascular occlusion and thrombosis seen in SCD and hemolytic uremic syndrome. Supports the underlying mechanistic rationale but does not test eptifibatide directly.

Germany Market Information

Eptifibatide currently has no marketing authorization on file for this market (未上市 / Not Marketed, 0 licenses recorded). No product/dosage-form/indication data is available to tabulate.

Safety Considerations

Please refer to the package insert for safety information. No structured warnings, contraindications, or drug-drug interaction data were retrievable for this evidence pack — this is flagged as a Blocking-severity data gap (DG001) in the source metadata, meaning this candidate cannot proceed to formal S1 safety evaluation until TFDA/BfArM package insert data is obtained and parsed.

Other TxGNN-Predicted Indications for This Drug

For transparency, the remaining 9 predictions in this multi-indication evidence pack are summarized below (all substantially lower in evidence maturity than hemoglobinopathy):

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Rheumatoid arthritis	99.99%	L5 (no trials/literature; rationale unfilled)	Pending
2	Hereditary persistence of fetal hemoglobin–sickle cell disease syndrome	99.98%	L5	Hold
3	Sickle cell–hemoglobin C disease syndrome	99.98%	L4 (1 tangential ACS bleeding-risk paper, not disease-specific)	Hold
4	Sickle cell–hemoglobin E disease syndrome	99.98%	L5	Hold
5	Sickle cell–beta-thalassemia disease syndrome	99.98%	L5	Hold
6	Sickle cell–hemoglobin D disease syndrome	99.98%	L5	Hold
7	Hemoglobinopathy (this report)	99.98%	L2	Research Question / Hold
8	Female breast carcinoma	99.97%	L4 (in vitro pro-apoptotic effect on MCF-7 cells; no in vivo/clinical data)	Research Question
9	Beta-thalassemia with other manifestations	99.97%	L5	Hold
10	Partial deletion of the short arm of chromosome 16	99.96%	L5 (mechanistic link considered weak — likely a genomic-proximity artifact, not a pharmacological one)	Hold

Notably, all 10 scores cluster within a narrow 99.96%–99.99% band, so TxGNN's raw ranking should not be read as a meaningful ordering of clinical plausibility — the evidence level differences (L2 vs. L4 vs. L5) are the more decision-relevant signal here.

Conclusion and Next Steps

Decision: Hold

Rationale: Hemoglobinopathy/sickle cell disease is the only prediction in this pack supported by actual human testing (a Phase 1 pharmacodynamic study and a pilot efficacy trial), but the confirmatory RCT (NCT00834899) was terminated early with a small cohort, and a Blocking-severity data gap (missing TFDA/BfArM label and safety data, DG001) prevents this candidate from entering formal safety evaluation regardless of indication.

To proceed, the following is needed:

Resolve DG001: obtain and parse the TFDA/BfArM package insert (warnings, contraindications, DDI) — currently blocking
Resolve DG002: obtain detailed mechanism of action data from DrugBank to strengthen the mechanistic-link analysis
Determine why NCT00834899 was terminated (recruitment, safety signal, or sponsor decision) before considering any renewed trial
If pursuing further research, prioritize hemoglobinopathy/sickle cell disease over the other 9 predictions, given it is the only one with real prior human data
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.